Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

The Association between Acute Cardiac Injury and Outcomes of Hospitalized Patients with COVID-19: Long-term Follow-up Results from the Sina Hospital COVID-19 Registry, Iran

Soltani et al., The Journal of Tehran University Heart Center, doi:10.18502/jthc.v18i3.14114
Nov 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Acute cardiac injury 25% Improvement Relative Risk HCQ for COVID-19  Soltani et al.  LATE TREATMENT c19hcq.org FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 419 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 110 treatments. c19hcq.org
Retrospective 1,413 hospitalized COVID-19 patients evaluating the association between acute cardiac injury (ACI) and outcomes. Authors include a multivariable analysis showing lower risk of ACI with HCQ and higher risk with remdesivir, without statistical significance.
Study covers HCQ and remdesivir.
acute cardiac injury, 24.7% lower, OR 0.75, p = 0.10, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Soltani et al., 21 Nov 2023, retrospective, Iran, peer-reviewed, 9 authors, study period March 2020 - March 2021.
This PaperHCQAll
The Association between Acute Cardiac Injury and Outcomes of Hospitalized Patients with COVID-19: Long-Term Follow-up Results from the Sina Hospital COVID-19 Registry, Iran
MD Danesh Soltani, MD Azar Hadadi, MD Shahrokh Karbalai Saleh, MD Alireza Oraii, MD Azadeh Sadatnaseri, MD Mostafa Roozitalab, MD Zahra Shajari, MD Shima Sadat Ghaemmaghami, MD Haleh Ashraf
Background: The present study aimed to investigate the association between acute cardiac injury (ACI) and outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19) in Iran. Methods: The current cohort study enrolled all consecutive hospitalized patients with COVID-19 (≥ 18 y) who had serum high-sensitivity cardiac troponin-I (hs-cTnT) measurements on admission between March 2020 and March 2021. ACI was determined as hs-cTnT levels exceeding the 99th percentile of normal values. Data on demographics, comorbidities, clinical and laboratory characteristics, and outcomes were collected from Web-based electronic health records. Results: The study population consisted of 1413 hospitalized patients with COVID-19, of whom 319 patients (22.58%) presented with ACI. The patients with ACI had a significantly higher mortality rate than those without ACI (48.28% vs 15.63%; P<0.001) within a mean follow-up of 218.86 days from symptom onset. ACI on admission was independently associated with mortality (HR, 1.44; P=0.018). In multivariable logistic regression, age (OR, 1.034; P<0.001), preexisting cardiac disease (OR, 1.49; P=0.035), preexisting malignancy (OR, 2.01; P=0.030), oxygen saturation reduced to less than 90% (OR, 2.15; P<0.001), leukocytosis (OR, 1.45; P=0.043), lymphopenia (OR, 1.49; P=0.020), reduced estimated glomerular filtration rates (eGFRs) (OR, 0.99; P=0.008), and treatment with intravenous immunoglobulin during hospitalization (OR, 4.03; P=0.006) were independently associated with ACI development. Conclusion: ACI occurrence on admission was associated with long-term mortality in our hospitalized patients with COVID-19. The finding further underscores the significance of evaluating ACI occurrence on admission, particularly in individuals more prone to ACI, including older individuals and those with preexisting comorbidities, reduced oxygen saturation, and increased inflammatory responses.
Supplementary Material
References
Ards Definition, Force, Ranieri, Rubenfeld, Thompson et al., Acute respiratory distress syndrome: the Berlin Definition, JAMA
Bavishi, Bonow, Trivedi, Abbott, Messerli et al., Special Article -Acute myocardial injury in patients hospitalized with COVID-19 infection: A review, Prog Cardiovasc Dis
Bernheim, Mei, Huang, Yang, Fayad et al., Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection, Radiology
Davé, Hagan, Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration, Ann Allergy Asthma Immunol
Egbuche, Jegede, Abe, Wagle, Huynh et al., Pre-existing cardiovascular disease, acute kidney injury, and cardiovascular outcomes in hospitalized blacks with COVID-19 infection, Am J Cardiovasc Dis
Elkayam, Paran, Milo, Davidovitz, Almoznino-Sarafian et al., Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases, Ann Rheum Dis
Figliozzi, Masci, Ahmadi, Tondi, Koutli et al., Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis, Eur J Clin Invest
Guo, Fan, Chen, Wu, Zhang et al., Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19), JAMA Cardiol
Huang, Huang, Du, Kong, Zhang et al., Prevalence and clinical outcomes of cardiac injury in patients with COVID-19: A systematic review and meta-analysis, Nutr Metab Cardiovasc Dis
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Karahan, Katkat, Ozcan, Sahin, Okuyan, Impact of acute myocardial injury on prognosis in patients with COVID-19, Eur Rev Med Pharmacol Sci
Kellum, Van Till, Mulligan, Targeting acute kidney injury in COVID-19, Nephrol Dial Transplant
Knight, Ho, Pius, Buchan, Carson et al., Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score, BMJ
Lala, Johnson, Januzzi, Russak, Paranjpe et al., Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection, J Am Coll Cardiol
Li, Pan, Li, Xing, Yang et al., Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review, Crit Care
Li, Xu, Huang, Fei, Xie et al., Acute cardiac injury and acute kidney injury associated with severity and mortality in patients with COVID-19, Eur Rev Med Pharmacol Sci
Manocha, Kirzner, Ying, Yeo, Peltzer et al., Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID-19: Derivation and Validation of the HA2T2 COVID-19 Mortality Risk Score, J Am Heart Assoc
Manolis, Manolis, Manolis, COVID-19 and Acute Myocardial Injury and Infarction: Related Mechanisms and Emerging Challenges, J Cardiovasc Pharmacol Ther
Mccarthy, Raber, Chapman, Sandoval, Apple et al., Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians, JAMA Cardiol
Musher, Abers, Vf, Acute Infection and Myocardial Infarction, N Engl J Med
Organization, Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected, Interim guidance
Saleh, Oraii, Soleimani, Hadadi, Shajari et al., The association between cardiac injury and outcomes in hospitalized patients with COVID-19, Intern Emerg Med
Salehi, Abedi, Balakrishnan, Gholamrezanezhad, Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients, AJR Am J Roentgenol
Sandoval, Januzzi, Jr, Jaffe, Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week, J Am Coll Cardiol
Shi, Qin, Shen, Cai, Liu et al., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China, JAMA Cardiol
Sinclair, Zhu, Xu, Ma, Shi et al., A meta-analysis on the role of pre-existing chronic disease in the cardiac complications of SARS-CoV-2 infection, iScience
Soltani, None
Uribarri, Núñez-Gil, Aparisi, Becerra-Muñoz, Feltes et al., Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry, J Nephrol
Wibowo, Pranata, Akbar, Purnomowati, Martha, Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression, Int J Infect Dis
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med
Zou, Qian, Wang, Zhao, Bai, Cardiac Injury and COVID-19: A Systematic Review and Meta-analysis, CJC Open
{ 'indexed': {'date-parts': [[2024, 1, 1]], 'date-time': '2024-01-01T07:40:40Z', 'timestamp': 1704094840588}, 'reference-count': 0, 'publisher': 'Knowledge E DMCC', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>Background: The present study aimed to investigate the association between acute ' 'cardiac injury (ACI) and outcomes in hospitalized patients with coronavirus disease 2019 ' '(COVID-19) in Iran.&#x0D;\n' 'Methods: The current cohort study enrolled all consecutive hospitalized patients with ' 'COVID-19 (≥ 18 y) who had serum high-sensitivity cardiac troponin-I (hs-cTnT) measurements on ' 'admission between March 2020 and March 2021. ACI was determined as hs-cTnT levels exceeding ' 'the 99th percentile of normal values. Data on demographics, comorbidities, clinical and ' 'laboratory characteristics, and outcomes were collected from Web-based electronic health ' 'records.&#x0D;\n' 'Results: The study population consisted of 1413 hospitalized patients with COVID-19, of whom ' '319 patients (22.58%) presented with ACI. The patients with ACI had a significantly higher ' 'mortality rate than those without ACI (48.28% vs 15.63%; P&lt;0.001) within a mean follow-up ' 'of 218.86 days from symptom onset. ACI on admission was independently associated with ' 'mortality (HR, 1.44; P=0.018). In multivariable logistic regression, age (OR, 1.034; ' 'P&lt;0.001), preexisting cardiac disease (OR, 1.49; P=0.035), preexisting malignancy (OR, ' '2.01; P=0.030), oxygen saturation reduced to less than 90% (OR, 2.15; P&lt;0.001), ' 'leukocytosis (OR, 1.45; P=0.043), lymphopenia (OR, 1.49; P=0.020), reduced estimated ' 'glomerular filtration rates (eGFRs) (OR, 0.99; P=0.008), and treatment with intravenous ' 'immunoglobulin during hospitalization (OR, 4.03; P=0.006) were independently associated with ' 'ACI development.&#x0D;\n' 'Conclusion: ACI occurrence on admission was associated with long-term mortality in our ' 'hospitalized patients with COVID-19. The finding further underscores the significance of ' 'evaluating ACI occurrence on admission, particularly in individuals more prone to ACI, ' 'including older individuals and those with preexisting comorbidities, reduced oxygen ' 'saturation, and increased inflammatory responses.</jats:p>', 'DOI': '10.18502/jthc.v18i3.14114', 'type': 'journal-article', 'created': { 'date-parts': [[2023, 11, 21]], 'date-time': '2023-11-21T12:45:51Z', 'timestamp': 1700570751000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The Association between Acute Cardiac Injury and Outcomes of Hospitalized Patients with ' 'COVID-19: Long-term Follow-up Results from the Sina Hospital COVID-19 Registry, Iran', 'prefix': '10.18502', 'author': [ {'given': 'Danesh', 'family': 'Soltani', 'sequence': 'first', 'affiliation': []}, {'given': 'Azar', 'family': 'Hadadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shahrokh Karbalai', 'family': 'Saleh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alireza', 'family': 'Oraii', 'sequence': 'additional', 'affiliation': []}, {'given': 'Azadeh', 'family': 'Sadatnaseri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mostafa', 'family': 'Roozitalab', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zahra', 'family': 'Shajari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shima Sadat', 'family': 'Ghaemmaghami', 'sequence': 'additional', 'affiliation': []}, {'given': 'Haleh', 'family': 'Ashraf', 'sequence': 'additional', 'affiliation': []}], 'member': '7770', 'published-online': {'date-parts': [[2023, 11, 21]]}, 'container-title': 'The Journal of Tehran University Heart Center', 'original-title': [], 'deposited': { 'date-parts': [[2024, 1, 1]], 'date-time': '2024-01-01T07:25:05Z', 'timestamp': 1704093905000}, 'score': 1, 'resource': { 'primary': {'URL': 'https://publish.kne-publishing.com/index.php/JTHC/article/view/14114'}, 'secondary': [{'URL': 'https://jthc.tums.ac.ir/index.php/jthc/article/view/1745'}]}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11, 21]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.18502/jthc.v18i3.14114', 'relation': {}, 'ISSN': ['2008-2371', '1735-8620'], 'subject': ['Cardiology and Cardiovascular Medicine'], 'container-title-short': 'JTHC', 'published': {'date-parts': [[2023, 11, 21]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit